Companies Partner on Alzheimer’s Disease Diagnostic Using Optimer Binders
Aptamer Group plc and Neuro-Bio have developed Optimer binders to enable a lateral flow test for the early diagnosis of Alzheimer’s disease.
Read MorePosted by Melanie Hamilton-Basich | Jun 20, 2023 | Dementias & Alzheimer’s, Rapid Assays |
Aptamer Group plc and Neuro-Bio have developed Optimer binders to enable a lateral flow test for the early diagnosis of Alzheimer’s disease.
Read MorePosted by Chris Wolski | Jun 15, 2023 | Clinical Chemistry |
The onus is on clinical laboratories to process a high volume of clinical chemistry tests as efficiently and accurately as possible.
Read MorePosted by Melanie Hamilton-Basich | Jun 14, 2023 | Molecular Diagnostics, Unknown Origin & Other Cancer Types |
Precipio’s HemeScreen Cytopenia panel enabled a patient’s diagnosis without the need for a painful, invasive bone marrow biopsy.
Read MorePosted by Melanie Hamilton-Basich | Jun 13, 2023 | Hematology & Serology, Prenatal Testing |
The test can be used between 23 and 35 weeks of pregnancy to predict development of severe preeclampsia among women who have symptoms of, or have been diagnosed with, hypertension during pregnancy.
Read MorePosted by Melanie Hamilton-Basich | Jun 13, 2023 | Cancer, Molecular Diagnostics |
Pfizer and Thermo Fisher Scientific Inc. have entered into a collaboration agreement to help increase local access to next-generation sequencing-based testing for lung and breast cancer patients.
Read More